Operating Income for Alnylam Pharmaceuticals (ALNY)
According to Alnylam Pharmaceuticals's latest reported financial statements, the company's current operating income (TTM) is $501.58M USD. Operating income is profit from core operations: revenue minus cost of goods sold and operating expenses (SG&A, R&D). It excludes interest, taxes, and non-operating items, so it isolates how profitable the business itself is before financing and tax decisions. Compare with EBITDA and net income.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Currently viewingOperating IncomeSwitch metric
TTM (last 4 quarters)
$501.58M
YoY change
-383.6%
5Y CAGR
N/A
Peak year (2025)
$501.58M
Cumulative operating income
-$6.29B
Operating Income history chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
Operating Income history table for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
| Fiscal year | Period ended | Reported | Operating Income | YoY |
|---|---|---|---|---|
| 2025 | $501.58M | -383.6% | ||
| 2024 | -$176.88M | -37.3% | ||
| 2023 | -$282.18M | -64.1% | ||
| 2022 | -$785.07M | +10.8% | ||
| 2021 | -$708.65M | -14.5% | ||
| 2020 | -$828.44M | -11.8% | ||
| 2019 | -$939.43M | +15.3% | ||
| 2018 | -$814.67M | +62.9% | ||
| 2017 | -$500.09M | +17.8% | ||
| 2016 | -$424.59M | +43.4% | ||
| 2015 | -$296.01M | -26.9% | ||
| 2014 | -$404.98M | +335.7% | ||
| 2013 | -$92.94M | -28.2% | ||
| 2012 | -$129.46M | +136.2% | ||
| 2011 | -$54.82M | +24.4% | ||
| 2010 | -$44.07M | -8.4% | ||
| 2009 | -$48.11M | +72.8% | ||
| 2008 | -$27.84M | -70.1% | ||
| 2007 | -$93.18M | +135.9% | ||
| 2006 | -$39.50M | -9.1% | ||
| 2005 | -$43.47M | +34.7% | ||
| 2004 | -$32.26M | +28.8% | ||
| 2003 | -$25.06M | +493.5% | ||
| 2002 | -$4.22M | — |
Operating Income values are taken from Alnylam Pharmaceuticals's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
Alnylam Pharmaceuticals (ALNY) most recent annual operating income stands at $501.58M (2025) – plunged 383.6% year-over-year.
The highest annual operating income of $501.58M was reported in 2025. The lowest in the available history was -$939.43M in 2019.
Alnylam Pharmaceuticals (ALNY) sits 9th of 8 Healthcare peers we track on this metric, against a peer median of $22.84B.
Alnylam Pharmaceuticals Operating Income by Year
Alnylam Pharmaceuticals Operating Income 2025: $501.58M
Alnylam Pharmaceuticals operating income in 2025 was $501.58M, plunged 383.6% below 2024. This figure represents the highest annual value in the available history.
Alnylam Pharmaceuticals Operating Income 2024: -$176.88M
Alnylam Pharmaceuticals operating income in 2024 was -$176.88M, plunged 37.3% below 2023.
Alnylam Pharmaceuticals Operating Income 2023: -$282.18M
Alnylam Pharmaceuticals operating income in 2023 was -$282.18M, plunged 64.1% below 2022.
Alnylam Pharmaceuticals Operating Income 2022: -$785.07M
Alnylam Pharmaceuticals operating income in 2022 was -$785.07M, grew 10.8% from 2021.
Alnylam Pharmaceuticals Operating Income 2021: -$708.65M
Alnylam Pharmaceuticals operating income in 2021 was -$708.65M.
See more financial history for Alnylam Pharmaceuticals (ALNY).
Sector peers — Operating Income
Companies in the same sector as Alnylam Pharmaceuticals, ranked by their latest operating income.
| Company | Operating Income | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $127.66B | Healthcare |
| Eli Lilly and Company (LLY) | $29.70B | Healthcare |
| Merck & Co., Inc. (MRK) | $26.78B | Healthcare |
| Johnson & Johnson (JNJ) | $25.60B | Healthcare |
| AbbVie Inc. (ABBV) | $20.09B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $18.96B | Healthcare |
| AstraZeneca PLC (AZN) | $13.74B | Healthcare |
| Amgen Inc. (AMGN) | $10.68B | Healthcare |
Frequently asked questions
What is Alnylam Pharmaceuticals's operating income?
- Latest reported operating income for Alnylam Pharmaceuticals (ALNY) is $501.58M (period ending December 31, 2025).
How has Alnylam Pharmaceuticals operating income changed year-over-year?
- Alnylam Pharmaceuticals (ALNY) operating income changed -383.6% year-over-year on the latest annual filing.
When did Alnylam Pharmaceuticals operating income hit its highest annual value?
- Alnylam Pharmaceuticals operating income reached its highest annual value of $501.58M in 2025.
What was Alnylam Pharmaceuticals operating income in 2024?
- Alnylam Pharmaceuticals (ALNY) operating income in 2024 was -$176.88M.
What was Alnylam Pharmaceuticals operating income in 2025?
- Alnylam Pharmaceuticals (ALNY) operating income in 2025 was $501.58M.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
ALNY Overview
Company profile, financial tools, and key metrics
ALNY Revenue Counter
Earns $117.77 every second. See per minute, hour, and day.
ALNY Earnings Counter
Earns $9.95 per second net profit. See per minute, hour, and day.
ALNY Economic Scale
Exceeds Curacao's GDP. Compare with world economies.
ALNY What If Invested
What if you had invested $1,000? See historical returns from any date.
ALNY How It Makes Money
Discover visual breakdown of $3.71B in revenue — where it comes from and where it goes.
ALNY Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
ALNY Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
ALNY Daily Price Character
Explosive · 50.6% historical win rate (green days). Streaks & record days.
ALNY Buybacks
Recent repurchase activity. Shareholder yield & SBC comparison.